Minor Cannabinoid Compositions for CIPN and SFN Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chemotherapy-induced peripheral neuropathy (CIPN) and small fiber neuropathy (SFN) often fail to alleviate pain effectively, and the underlying mechanisms are not well understood.
Innovation Solution
Administering a composition comprising one or more minor cannabinoids, such as CBG, CBGA, CBN, THCV, THCA, CBC, CBCA, CBDV, and D8-THC, optionally with THC and CBD, to modulate biomarkers of central and peripheral sensitization, thereby reducing pain and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved therapies (TCAs, SNRIs, anticonvulsants, opioids) are used to treat small fiber neuropathy pain, then pain relief is attempted, but effectiveness is insufficient and side effects occur
Solution Approach 1:
The patent changes the chemical parameter by using cannabinoids (THC, CBD, and minor cannabinoids) instead of conventional FDA-approved therapies. This parameter change aims to achieve effective pain relief while reducing side effects associated with traditional treatments like TCAs, SNRIs, anticonvulsants, and opioids.
Solution Approach 2:
The patent employs composite cannabinoid formulations combining multiple cannabinoids (THC, CBD, and minor cannabinoids like CBG, CBN, THCV, CBC, etc.) in specific ratios. This composite approach leverages the synergistic effects of different cannabinoids to improve pain relief effectiveness while minimizing side effects compared to single-agent therapies.
2Reliability
If THC is used to reduce pain, then analgesic effect is achieved, but psychoactive side effects and risk factors increase
Solution Approach 1:
The patent merges THC with CBD and minor cannabinoids in specific formulations. The CBD component acts to reduce the psychoactive side effects of THC while maintaining its analgesic benefits. This combination approach allows for effective pain relief with minimized psychoactive adverse effects.
Solution Approach 2:
CBD serves as an intermediary substance that modulates the psychoactive effects of THC. By including CBD in the cannabinoid formulation, the patent reduces the unwanted psychoactive side effects while preserving the pain-relieving properties of THC.
3Ease of manufacture
If conventional neuropathy treatments are used, then standard care is provided, but underlying mechanisms remain poorly understood and treatment efficacy is limited
Solution Approach 1:
The patent introduces a new therapeutic parameter by using cannabinoid compositions with specific ratios of major and minor cannabinoids. This parameter change addresses the limitations of conventional treatments by providing a mechanism-based approach that targets central and peripheral sensitization pathways involved in neuropathic pain.
Data Source
AI summary
The present disclosure is related to the use of compositions and their use in reducing pain associated with small fiber neuropathies, and in particular chemotherapy induced peripheral neuropathy.